


protein can have direct and indirect benefits in a variety of inflammatory disorders of multiple organs, for example, in treating psoriasis (Lowes et al, Ann Review Immunology, 32, 227-55, 2014; Afonina et al., EMBO Reports, 1-14, 2016; Howes et al., Biochem J, 1-23, 2016), multiple sclerosis (Jabara et al., J Allergy Clin Immunology, 132, 151-58, 2013; McGuire et al., J of Neuroinflammation, 11, 1-12, 2014), rheumatoid arthritis, Sjogren's syndrome (Streubel et al., Clin Cancer Research, 10, 476-80, 2004; Sagaert et al., Modern Pathology, 19, 225-32, 2006), ulcerative colitis (Liu et al., Oncotarget, 1-14, 2016), MALT lymphomas of different organs (Suzuki et al., Blood, 94, 3270-71, 1999; Akagi et al., Oncogene, 18, 5785-94, 1999) and different types of allergic disorders resulting from chronic inflammation.

In addition, several patent applications related to MALT1 are published which are as follows: WO 2008 146259, WO 2009 065897, WO 2013 017637, WO 2013 053765, WO 2014 074815, WO 2014 086478, WO 2014 207067, WO 2015 110406, WO 2015 181747, WO 2016 193339, WO 2017 040304, WO 2017 057695, and WO 2017 081641.

The foregoing shows that there exists an unmet need for MALT1 inhibitory compounds for treating diseases or disorders involving MALT1 activation, particularly cancers as well as inflammatory disorders that are dependent on the MALT1-NF- κ B axis.

SUMMARY


The present disclosure provides compounds of the general formula (I), their pharmaceutically acceptable salts, tautomeric forms, stereoisomers, polymorphs, solvates, combinations with suitable other medicament or medicaments and pharmaceutical compositions thereof and use thereof in treating various diseases or disorders including cancers.



wherein, R¹-R³ are described in detail below. The compounds of the present disclosure are potent inhibitors of MALT1.

Disclosed is a compound represented by the general formula (I), its tautomeric form, its stereoisomer, its polymorph, its solvate, its pharmaceutically acceptable salt, its combinations with suitable medicament and its pharmaceutical compositions, wherein, R¹-R³ are described in detail below.

In one aspect, there is provided a compound of the general formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof,



wherein,

R¹ is selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, and cycloalkyl;

R² is selected from -

a) alkyl or alkyl substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, cycloalkyl, substituted or unsubstituted aryl, heteroaryl, substituted or unsubstituted heterocyclyl, -OR⁴, -C(=O)OH, -SO₂(alkyl), -C(=O)O(alkyl), -NR⁵R^{5a}, -NR⁵C(=O)R⁶, -C(=O)R⁶, and -C(=O)NR⁵R^{5a},


4a

- b) cycloalkyl or cycloalkyl substituted with 1 to 4 substituents independently selected from halogen, cyano, substituted or unsubstituted alkyl, $-OR^4$, $-C(=O)OH$, $-C(=O)O(alkyl)$, $-C(=O)R^6$, and $-C(=O)NR^5R^{5a}$,
- c) cycloalkenyl,
- 5 d) cyano,
- e) substituted or unsubstituted aryl,
- f) substituted or unsubstituted heteroaryl,
- g) heterocyclyl or heterocyclyl substituted on either ring carbon atom or a ring nitrogen atom and when it is substituted on ring carbon atom it is substituted
- 10 with 1 to 4 substituents independently selected from oxo ($=O$), halogen, cyano, substituted or unsubstituted alkyl, cycloalkyl, $-OR^4$, $-C(=O)OH$, $-C(=O)O-alkyl$, $-C(=O)NR^5N^{5a}$, $-N(H)C(=O)(alkyl)$, $-N(H)R^5$, and $-N(alkyl)_2$, and when the heterocycle group is substituted on a ring nitrogen, it is substituted with
- 15 $SO_2(alkyl)$, $-C(=O)R^6$, $-C(=O)O(alkyl)$, $-C(=O)N(H)R^5$, and $-C(=O)N(alkyl)R^5$, and
- h) $-NR^aR^b$, wherein, R^a and R^b are independent selected from hydrogen, cycloalkyl, and alkyl or alkyl substituted with 1 to 4 substituents independently selected from oxo ($=O$), halogen, cycloalkyl, $-OR^4$, and substituted or unsubstituted aryl;
- 20 R^3 is selected from -
- a) heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from halogen, cyano, $-COOR^{4b}$, $-OR^{4a}$, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, $-SO_2alkyl$, $-SO_2NH(alkyl)$, $-SO_2NH_2$, -
- 25 $SO_2NH(CF_3)$, $-SO_2N(alkyl)_2$, $-NHSO_2(alkyl)$, $-COR^6$, $-CON(H)OH$, $-CONR^5R^{5a}$, $-N(R^5)COR^{5a}$, and $-NR^5R^{5a}$,
- b) aryl or aryl substituted with 1 to 4 substituents selected from halogen, cyano, $-COOR^{4b}$, $-OR^{4a}$, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, $-SO_2alkyl$,

4b

-SO₂NH(alkyl), -SO₂NH₂, -SO₂NH(CF₃), -SO₂N(alkyl)₂, -NHSO₂(alkyl), -COR⁶, -CONR⁵R^{5a}, -CO(NH)OH, -N(R⁵)COR^{5a}, -NR⁵R^{5a}, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyl,

- 5 c) heterocyclyl or heterocyclyl substituted with 1 to 4 substituents selected from oxo (=O) and substituted or unsubstituted alkyl, and



d) , wherein, X is halogen and ring A is a heterocyclic ring containing heteroatom(s) selected from S, O, and N, which is optionally substituted with an oxo (=O) group;

- 10 R⁴ is selected from hydrogen, cycloalkyl, and substituted or unsubstituted alkyl;

R^{4a} is selected from

a) hydrogen, alkyl, and cycloalkyl, and

b) alkyl substituted with 1 to 4 substituents independently selected from halogen, -O-alkyl, -NR⁵R^{5a}, and substituted or unsubstituted heterocyclyl;

- 15 R^{4b} is selected from hydrogen and alkyl;

R⁵ and R^{5a} are each independently selected from

a) hydrogen, alkyl, and cycloalkyl,

b) alkyl substituted with -O-alkyl, -NH₂, and -CONH₂,

c) heteroaryl, and

- 20 d) heterocyclyl substituted with alkyl; and

R⁶ is selected from alkyl, heterocyclyl, and cycloalkyl;

when an alkyl group is substituted, it is substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, cycloalkyl, aryl,

heteroaryl, heterocyclyl, -OR⁷, -C(=O)OH, -C(=O)O(alkyl), -NR⁸R^{8a}, -NR⁸C(=O)R⁹, and -C(=O)NR⁸R^{8a};

when the aryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, perhaloalkyl, cycloalkyl, heterocyclyl, heteroaryl, -OR⁷, -NR⁸R^{8a}, -NR⁸C(=O)R⁹, -C(=O)R⁹, -C(=O)NR⁸R^{8a}, -SO₂-alkyl, -C(=O)OH, -C(=O)O-alkyl, and haloalkyl;

when the heteroaryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, haloalkyl, perhaloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR⁷, -NR⁸R^{8a}, -NR⁷C(=O)R⁹, -C(=O)R⁹, -C(=O)NR⁸R^{8a}, -SO₂-alkyl, -C(=O)OH, and -C(=O)O-alkyl;

when the heterocycle group is substituted, it is substituted either on a ring carbon atom or on a ring hetero atom, and when it is substituted on a ring carbon atom, it is substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, alkyl, cycloalkyl, perhaloalkyl, -OR⁷, -C(=O)NR⁸R^{8a}, -C(=O)OH, -C(=O)O-alkyl, -N(H)C(=O)(alkyl), -N(H)R⁸, and -N(alkyl)₂; and when the heterocycle group is substituted on a ring nitrogen, it is substituted with substituents independently selected from alkyl, cycloalkyl, aryl, heteroaryl, -SO₂(alkyl), -C(=O)R⁹, and -C(=O)O(alkyl); when the heterocycle group is substituted on a ring sulfur, it is substituted with 1 or 2 oxo (=O) group(s);

R⁷ is selected from hydrogen, alkyl, perhaloalkyl, and cycloalkyl;

R⁸ and R^{8a} are each independently selected from hydrogen, alkyl, and cycloalkyl; and

R⁹ is selected from alkyl and cycloalkyl.

In another aspect, there is provided a pharmaceutical composition comprising a compound disclosed herein, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present disclosure provides a pharmaceutical composition, containing the compound of the general formula (I) as defined herein, its

tautomeric form, and its stereoisomer, its polymorph, its solvate, its pharmaceutically acceptable salt in combination with the usual pharmaceutically employed carriers, diluents, and the like are useful for the treatment of a disease or disorder mediated through MALT1.

- 5 The present disclosure provides a pharmaceutical composition, containing the compound of the general formula (I) as defined herein, its tautomeric form, its stereoisomer, its polymorph, its solvate, and its pharmaceutically acceptable salt in combination with the usual pharmaceutically employed carriers, diluents, and the like are useful for the treatment of a disease or disorder such
10 as cancer, inflammation or inflammatory disease or disorder, or allergic or autoimmune disease or disorder.

- The present disclosure provides a pharmaceutical composition, containing the compound of the general formula (I) as defined herein, its tautomeric form, its stereoisomer, its polymorph, its solvate, and its pharmaceutically acceptable
15 salt in combination with the usual pharmaceutically employed carriers, diluents, and the like are useful for the treatment of a disease or disorder such as ABC-DLBCL type of lymphomas, a subset of GCB-DLBCL type of lymphomas involving MALT1, MALT lymphomas, mantle cell lymphoma, marginal zone

lymphoma, cutaneous T cell lymphomas, primary effusion lymphoma, pancreatic cancer, chronic lymphocytic leukemia with CARD11 mutation, Hodgkin's and Non-Hodgkin's lymphomas, or a subset of acute myelogenous leukemia involving MALT1, germ cell tumors and neoplasm involving plasma
5 cell, brain tumors including glioblastoma, hepatic adenomas, medulloblastoma, mesothelioma, different types of melanomas and multiple myeloma, clear cell carcinoma, or adenocarcinoma of lung, breast, bladder, skin, brain, colon, stomach, cervix, ovary, uterus, prostate, liver, and kidney, psoriasis, multiple sclerosis, systemic lupus erythematosus, BENTA disease, ulcerative colitis,
10 pancreatitis, rheumatic fever, or rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, gastritis, celiac disease, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, Behcet's disease, uveitis, dermatitis including atopic dermatitis, dermatomyositis, inflammation of skeletal muscles leading to
15 polymyositis, myasthenia gravis, Grave's disease, Hashimoto thyroiditis, blistering disorders, vasculitis syndromes, Hennoch-Schonlein Purpura, or immune-complex vasculitides, Sjoren's syndrome, asthma, bronchitis, or chronic obstructive pulmonary disease, cystic fibrosis, and respiratory diseases involving lungs leading to respiratory distress and failure.

20 In another aspect, there is provided a compound disclosed herein, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, for use in treating a disease or disorder mediated through MALT1 in a subject in need thereof.


In another aspect, there is provided use of a compound disclosed herein, a
25 tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease or disorder mediated through MALT1 in a subject in need thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is related to a compound of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, its solvate, its combination with suitable one or more other
5 medicaments, its pharmaceutical composition, method of making of the compound, its use as MALT1 inhibitor, and its therapeutic utility in treating, or ameliorating various pathological conditions. The compounds are of formula (I) below:

CLAIMS

1. A compound of the general formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof,



wherein,

R¹ is selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, and cycloalkyl;

- 10 R² is selected from -

a) alkyl or alkyl substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, cycloalkyl, substituted or unsubstituted aryl, heteroaryl, substituted or unsubstituted heterocyclyl, -OR⁴, -C(=O)OH, -SO₂(alkyl), -C(=O)O(alkyl), -NR⁵R^{5a}, -NR⁵C(=O)R⁶, -C(=O)R⁶, and -C(=O)NR⁵R^{5a},

- 15 b) cycloalkyl or cycloalkyl substituted with 1 to 4 substituents independently selected from halogen, cyano, substituted or unsubstituted alkyl, -OR⁴, -C(=O)OH, -C(=O)O(alkyl), -C(=O)R⁶, and -C(=O)NR⁵R^{5a},

c) cycloalkenyl,

d) cyano,

- 20 e) substituted or unsubstituted aryl,

f) substituted or unsubstituted heteroaryl,

g) heterocyclyl or heterocyclyl substituted on either ring carbon atom or a ring nitrogen atom and when it is substituted on ring carbon atom it is substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano,

substituted or unsubstituted alkyl, cycloalkyl, -OR⁴, -C(=O)OH, -C(=O)O-alkyl, -C(=O)NR⁵N^{5a}, -N(H)C(=O)(alkyl), -N(H)R⁵, and -N(alkyl)₂, and when the heterocycle group is substituted on a ring nitrogen, it is substituted with substituents independently selected from alkyl, cycloalkyl, aryl, heteroaryl, -SO₂(alkyl), -C(=O)R⁶, -C(=O)O(alkyl), -C(=O)N(H)R⁵, and -C(=O)N(alkyl)R⁵, and


h) -NR^aR^b, wherein, R^a and R^b are independent selected from hydrogen, cycloalkyl, and alkyl or alkyl substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cycloalkyl, -OR⁴, and substituted or unsubstituted aryl;

10 R³ is selected from -

a) heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from halogen, cyano, -COOR^{4b}, -OR^{4a}, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, -SO₂alkyl, -SO₂NH(alkyl), -SO₂NH₂, -SO₂NH(CF₃), -SO₂N(alkyl)₂, -NHSO₂(alkyl), -COR⁶, -CON(H)OH, -CONR⁵R^{5a}, -N(R⁵)COR^{5a}, and -NR⁵R^{5a},

b) aryl or aryl substituted with 1 to 4 substituents selected from halogen, cyano, -COOR^{4b}, -OR^{4a}, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, -SO₂alkyl, -SO₂NH(alkyl), -SO₂NH₂, -SO₂NH(CF₃), -SO₂N(alkyl)₂, -NHSO₂(alkyl), -COR⁶, -CONR⁵R^{5a}, -CO(NH)OH, -N(R⁵)COR^{5a}, -NR⁵R^{5a}, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyl,

c) heterocyclyl or heterocyclyl substituted with 1 to 4 substituents selected from oxo (=O) and substituted or unsubstituted alkyl, and



d) , wherein, X is halogen and ring A is a heterocyclic ring containing heteroatom(s) selected from S, O, and N, which is optionally substituted with an oxo (=O) group;

R⁴ is selected from hydrogen, cycloalkyl, and substituted or unsubstituted alkyl;

5 R^{4a} is selected from

a) hydrogen, alkyl, and cycloalkyl, and

b) alkyl substituted with 1 to 4 substituents independently selected from halogen, -O-alkyl, -NR⁵R^{5a}, and substituted or unsubstituted heterocyclyl;

R^{4b} is selected from hydrogen and alkyl;

10 R⁵ and R^{5a} are each independently selected from

a) hydrogen, alkyl, and cycloalkyl,

b) alkyl substituted with -O-alkyl, -NH₂, and -CONH₂,

c) heteroaryl, and

d) heterocyclyl substituted with alkyl; and

15 R⁶ is selected from alkyl, heterocyclyl, and cycloalkyl;

when an alkyl group is substituted, it is substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, cycloalkyl, aryl, heteroaryl, heterocyclyl, -OR⁷, -C(=O)OH, -C(=O)O(alkyl), -NR⁸R^{8a}, -NR⁸C(=O)R⁹, and -C(=O)NR⁸R^{8a};

20 when the aryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, perhaloalkyl, cycloalkyl, heterocyclyl, heteroaryl, -OR⁷, -NR⁸R^{8a}, -NR⁸C(=O)R⁹, -C(=O)R⁹, -C(=O)NR⁸R^{8a}, -SO₂-alkyl, -C(=O)OH, -C(=O)O-alkyl, and haloalkyl;

when the heteroaryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, haloalkyl, perhaloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR⁷, -NR⁸R^{8a}, -NR⁷C(=O)R⁹, -C(=O)R⁹, -C(=O)NR⁸R^{8a}, -SO₂-alkyl, -C(=O)OH, and -C(=O)O-alkyl;

5 when the heterocycle group is substituted, it is substituted either on a ring carbon atom or on a ring hetero atom, and when it is substituted on a ring carbon atom, it is substituted with 1 to 4 substituents independently selected from oxo (=O), halogen, cyano, alkyl, cycloalkyl, perhaloalkyl, -OR⁷, -C(=O)NR⁸R^{8a}, -C(=O)OH, -C(=O)O-alkyl, -N(H)C(=O)(alkyl), -N(H)R⁸, and -N(alkyl)₂; and when the heterocycle group is substituted on a ring nitrogen, it is substituted with substituents independently selected from alkyl, cycloalkyl, aryl, heteroaryl, -SO₂(alkyl), -C(=O)R⁹, and -C(=O)O(alkyl); when the heterocycle group is substituted on a ring sulfur, it is substituted with 1 or 2 oxo (=O) group(s);

15 R⁷ is selected from hydrogen, alkyl, perhaloalkyl, and cycloalkyl;

R⁸ and R^{8a} are each independently selected from hydrogen, alkyl, and cycloalkyl; and

R⁹ is selected from alkyl and cycloalkyl.

20 **2.** The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein R¹ is selected from hydrogen and substituted or unsubstituted alkyl.

25 **3.** The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in claim 1 or 2, wherein R¹ is selected from hydrogen, methyl, ethyl, and -CF₃.

4. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, wherein R² is selected from

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-(dimethylamino)-2,2,2-trifluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 231);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-ethyl-7-(1-methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 232);

- 5 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-ethyl-7-(1-methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 233);

1-(6-((S)-2-Aminopropoxy)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea hydrochloride (Compound 234);

- 10 1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(((R)-1-methoxypropan-2-yl)(methyl)amino)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 235);

1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(thiazol-2-ylamino)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 236);

- 15 N-(5-(3-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)ureido)-3-(trifluoromethyl)pyridin-2-yl)acetamide (Compound 237);

1-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(methoxymethyl)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 238);

1-(6-(1H-Tetrazol-1-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 239); and

- 20 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(2-cyclopropyl-1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 240).

- 15 **15.** A pharmaceutical composition comprising a compound of any one of claims 1 to 14, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

16. Use of a compound of any one of claim 1 to 14, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for

treating a disease or disorder mediated through MALT1 in a subject in need thereof.

17. The use as claimed in claim 16, wherein said disease or disorder is cancer, inflammation or inflammatory disease or disorder, or allergic or autoimmune disease or disorder.

18. The use as claimed in claim 17, wherein the said cancer is lymphoma or leukemia.

19. The use as claimed in claim 17, wherein the said cancer is ABC-DLBCL type of lymphomas, a subset of GCB-DLBCL type of lymphomas involving MALT1, MALT lymphomas, mantle cell lymphoma, marginal zone lymphoma, cutaneous T cell lymphomas, primary effusion lymphoma, pancreatic cancer, chronic lymphocytic leukemia with CARD11 mutation, Hodgkin's and Non-Hodgkin's lymphomas, or a subset of acute myelogenous leukemia involving MALT1.

20. The use as claimed in claim 17, wherein the said cancer is germ cell tumors and neoplasm involving plasma cell, brain tumors including glioblastoma, hepatic adenomas, medulloblastoma, mesothelioma, different types of melanomas and multiple myeloma, clear cell carcinoma, or adenocarcinoma of lung, breast, bladder, skin, brain, colon, stomach, cervix, ovary, uterus, prostate, liver, and kidney.

21. The use as claimed in claim 17, wherein the said inflammatory disease or disorder is psoriasis, multiple sclerosis, systemic lupus erythematosus, BENTA disease, ulcerative colitis, pancreatitis, rheumatic fever, or rheumatoid arthritis.

22. The use as claimed in claim 17, wherein said inflammatory disease or disorder is ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, gastritis, celiac disease, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, Behcet's disease, uveitis, dermatitis including atopic dermatitis, dermatomyositis, inflammation of skeletal muscles leading to polymyositis, myasthenia gravis, Grave's disease, Hashimoto thyroiditis, blistering disorders, vasculitis syndromes, Hennoch-Schonlein Purpura, or immune-complex vasculitides.

23. The use as claimed in claim 17, wherein the said allergic or autoimmune disease or disorder is Sjoren's syndrome, asthma, bronchitis, or chronic obstructive pulmonary disease.

5 **24.** The use as claimed in claim 17, wherein the said allergic or autoimmune disease or disorder is cystic fibrosis, respiratory diseases involving lungs leading to respiratory distress and failure.

25. The use as claimed in claim 24, whrein respiratory distress and failure means emphysema, pulmonary oedema, pulmonary embolism and primary pulmonary hypertension, and lung fibrosis due to Berylium poisoning.

10 **26.** A compound of any one of claims 1 to 14, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, for use in treating a disease or disorder mediated through MALT1 in a subject in need thereof.